Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

about

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

P2860

Q55205941-1567C5D1-8AAF-459F-B65F-96C982665141

P2860

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q38787405

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

@en

type

Item

label

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

@en

prefLabel

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

@en

P1476

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

@en

P2093

Anna Maria Scattolin

http://www.w3.org/2001/XMLSchema#string

Elena Maino

http://www.w3.org/2001/XMLSchema#string

Massimiliano Bonifacio

http://www.w3.org/2001/XMLSchema#string

Renato Bassan

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and subclassification of acute lymphoblastic leukemia

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.

P304

563-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2016.1170593

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27011303

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

about

P2860

P2860

Immunotherapy approaches to treat adult acute lymphoblastic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921